Search - tctmd.com

Displaying 801 - 820 of 1234

Sort: Relevancy | Date

REVASCTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

News Conference News TCT 2017

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

Todd Neale

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

Switzerland Presents: A Case of Severe Symptomatic Aortic Stenosis and Complex Coronary Artery Disease - ECMO Support?

Presenter: Hyo-Soo Kim, Quang Ngoc Nguyen, Stephane Noble

October 31, 2017

News Conference News TCT 2017

3-D Printing Opportunities Emerge for Cardiologists, Hospitals, and Device Companies Alike

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

Slovenia Presents: MitraClip in Severe Ischemic Heart Disease - Hybrid Treatment Approach

Presenter: Emmanouil I Skalidis, Matjaz Bunc

October 31, 2017

Presentation TCT 2017

When is TAVR Indicated for Low Gradient AS With Preserved Ejection Fraction? Case Examples

Presenter: Mackram F. Eleid

October 30, 2017

Presentation TCT 2017

Clinical Management of Low Flow-Low Gradient AS: The Role of TAVR

Presenter: Howard C. Herrmann

October 30, 2017

Presentation TCT 2017

Classifying Aortic Stenosis According to Pathophysiology and Hemodynamics An Echocardiographers Perspective

Presenter: Philippe Pibarot

October 30, 2017

Presentation TCT 2017

How to Optimally Perform Valve-in-Valve Implantation in a Small Surgical Valve (Including Bioprosthetic Valve Fracture) Case Examples

Presenter: Danny Dvir

October 30, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

Understanding Surgical Aortic Valve Anatomy: Implications for Valve-in-Valve Therapy

Presenter: Vinayak Bapat

October 30, 2017

Presentation TCT 2017

The NOTION 2 Low-risk Trial in Younger Patients

Presenter: Lars Sondergaard

October 30, 2017

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

The UK All-comer TAVI Study

Presenter: Neil E. Moat

October 30, 2017

Presentation TCT 2017

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Presenter: Thomas Walther

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Presenter: Martin B. Leon, Patrick T. O'Gara, Nicolas M. Van Mieghem

October 30, 2017

Presentation TCT 2017

Insights From the New 2017 ESC Valve Disease Guidelines: Changes in the Management of Aortic Stenosis

Presenter: Martin B. Leon, Patrick T. O'Gara, Olaf Wendler

October 30, 2017

Advertisement

REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief

Long-term Absorb BVS Data Continue to Disappoint

Switzerland Presents: A Case of Severe Symptomatic Aortic Stenosis and Complex Coronary Artery Disease - ECMO Support?

3-D Printing Opportunities Emerge for Cardiologists, Hospitals, and Device Companies Alike

Slovenia Presents: MitraClip in Severe Ischemic Heart Disease - Hybrid Treatment Approach

When is TAVR Indicated for Low Gradient AS With Preserved Ejection Fraction? Case Examples

Clinical Management of Low Flow-Low Gradient AS: The Role of TAVR

Classifying Aortic Stenosis According to Pathophysiology and Hemodynamics An Echocardiographers Perspective

How to Optimally Perform Valve-in-Valve Implantation in a Small Surgical Valve (Including Bioprosthetic Valve Fracture) Case Examples

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Understanding Surgical Aortic Valve Anatomy: Implications for Valve-in-Valve Therapy

The NOTION 2 Low-risk Trial in Younger Patients

The Evolut R Low-risk Trial

The PARTNER 3 Low-risk Trial

The UK All-comer TAVI Study

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Insights From the New 2017 ESC Valve Disease Guidelines: Changes in the Management of Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content